This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Osteoarthritis	Matrix metalloproteinase 13 (MMP13)	<p><i>In vitro</i> and tissue studies suggest that selective inhibitors of MMP13 could help treat osteoarthritis. <i>In vitro</i> testing identified a lead arylsulfonamide hydroxamate compound with low nanomolar activity against MMP13 and MMP2. The compound inhibited MMP13-induced collagen degradation <i>in vitro</i> and in porcine cartilage tissue samples at low nanomolar concentrations. Next steps could include testing the lead compound in animal models of osteoarthritis and determining whether MMP2 inhibition is beneficial or detrimental in treating the indication.</p> <p>SciBX 2(30); doi:10.1038/scibx.2009.1168 Published online Aug. 6, 2009</p>	Patent and licensing status unavailable	<p>Nuti, E. <i>et al. J. Med. Chem.</i>; published online July 16, 2009; doi:10.1021/jm900261f Contact: Armando Rossello, University of Pisa, Pisa, Italy e-mail: aros@farm.unipi.it</p>